No Data
No Data
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
Spyre Therapeutics Analyst Ratings
Spyre Therapeutics Price Target Raised to $65 From $50 at Guggenheim
Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Spyre Therapeutics Advances SPY003 for IBD Treatment
Paragon Therapeutics Granted Spyre Therapeutics An Exclusive License To Develop, Manufacture, And Commercialize Certain Antibodies And Products Targeting IL-23 For Irritable Bowel Disease, Paragon Will Receive $22M As Milestone Payments And Further...